Court Rejected AstraZeneca Motion in Arkansas 340B Case
The ruling forces pharmaceutical manufacturers to continue complying with state rules on 340B pharmacy access.
Updated on Sept. 30, 2026 in Healthcare
Live Poll
Should states be allowed to regulate how drug manufacturers contract with pharmacies for discount programs?
A U.S. District Court judge denied a summary judgment motion from AstraZeneca that sought to strike down the Arkansas 340B Drug Pricing Nondiscrimination Act. The decision mandates that manufacturers maintain pharmacy participation standards in Arkansas.
Why it matters
The ruling maintains current operational compliance requirements for drug manufacturers regarding their pharmacy contracts in Arkansas. Businesses affected by these state-level 340B mandates must continue to adhere to the existing nondiscrimination statutes while the litigation persists.
A federal court denied a motion for summary judgment in a case involving the Arkansas 340B Drug Pricing Nondiscrimination Act. The extent of the potential impact on future pharmacy contract terms remains unresolved as the litigation continues.
The players
AstraZeneca
A multinational pharmaceutical company focused on the development and commercialization of prescription medicines.
U.S. District Court for the Eastern District of Arkansas
The federal judicial body responsible for hearing and ruling on legal challenges to state statutes within its jurisdiction.
The details
AstraZeneca sought to invalidate the Arkansas law, which prohibits drug manufacturers from restricting the use of contract pharmacies within the 340B program. By denying the motion for summary judgment, the court requires that the manufacturer continue operating under the state's regulatory framework. Businesses involved in 340B network management in the state must continue to comply with the existing nondiscrimination provisions.
Timeline
The court denied the summary judgment motion on September 29, 2026.
Market Landscape
The ruling affirms the enforceability of the Arkansas 340B Drug Pricing Nondiscrimination Act despite ongoing manufacturer challenges. This decision follows a broader industry trend where states have increasingly implemented specific rules to protect pharmacy participation in federal drug pricing programs.
Operators in the Arkansas pharmaceutical supply chain should ensure their pharmacy network contracts remain fully compliant with the state's 340B nondiscrimination rules. Consult with legal counsel to assess how this ongoing litigation might shift future compliance requirements for your specific operations.
The takeaway
This ruling signals that the Arkansas 340B mandates remain in effect, requiring manufacturers to maintain consistent access for contract pharmacies. Business owners should monitor the Eastern District of Arkansas docket for further proceedings to adjust their compliance and contracting strategies accordingly.
Further reading
For more on industry compliance, see our coverage of Healthcare.
Source note: This article includes information reported by Bloomberglaw.
Live Poll
Should states be allowed to regulate how drug manufacturers contract with pharmacies for discount programs?
